Resistance-Nodulation-Cell Division-Type Efflux Pump Involved in Aminoglycoside Resistance in Acinetobacter baumannii Strain BM4454

By S. Magnet, P. Courvalin, T. Lambert. Antimicrobial Agents and Chemotherapy, 2001

606 citations recorded by the source corpus.

Subfields: Endocrinology, Molecular Medicine, Oncology

View Paper: https://www.semanticscholar.org/paper/59dc05568c6ec6032b65fdcec49e89098a915365

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology

1. L. Poirel
2. P. Nordmann
3. Jung Hun Lee
4. Chang-Ro Lee
5. B. Jeong
6. S. Lee
7. Kwang Seung Park
8. David L. Paterson

In Molecular Medicine

1. P. Nordmann
2. L. Poirel
3. Jung Hun Lee
4. Chang-Ro Lee
5. B. Jeong
6. S. Lee
7. Kwang Seung Park
8. David L. Paterson

In Oncology

1. L. Piddock

Citations in the corpus

• Aminoglycosides: An Overview. (2016, background): “…of the resistance–nodulation–division (RND) family of efflux systems have been shown to be involved in intrinsic aminoglycoside resistance in various pathogens (Aires et al. 1999; Westbrock-Wadman et al. 1999; Rosenberg et al. 2000; Magnet et al. 2001; Hocquet et al. 2003; Islam et al. 2004).”
• Comparative Genomics of Multidrug Resistance in Acinetobacter baumannii (2006, neutral): “adeB (32_436) Amg, fluo, tet, clo, ery, tri, EthBr No (CT025812) No A. baumannii (100%) [68] adeC (32_437) Amg, flu, tet, clo, ery, tri, EthBr No (CT025813) No A. baumannii (97%) [ 68 ] adeR (32_497) Amg, flu, tet, clo, ery, tri, EthBr No (CT025814) No A. baumannii (98%) [39] adeS (32_498) Amg, flu,”
• Antimicrobial activities of silver dressings: an in vitro comparison. (2006, background): “One major advantage of its use is the limited side effects of topical silver therapy; silver toxicity or argyrosis can be resolved with cessation of therapy (Lansdown, 2002b; Marshall & Schneider, 1977).”
• Acquired Antibiotic Resistance Genes: An Overview (2011, background): “M. Pilar Francino, Center for Public Health Research, Spain Jun Liu, Mount Sinai School of Medicine, USA *Correspondence: Henk J. M. Aarts, National Institute of Public Health and the Environment, Antonie van Leeuwenhoekla 9, 3721 MA Bilthoven, Utrecht, Netherlands. e-mail: henk.aarts@rivm.nl In…”
• Acinetobacter baumannii: Emergence of a Successful Pathogen (2008, background): “Apart from tetracycline-specific efflux pumps, this class of antimicrobials is also susceptible to efflux by the multidrug efflux systems, such as the AdeABC pump (347).”
• Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. (2006, background): “Its role in resistance to aminoglycosides and in decreased susceptibility to chloramphenicol, fluoroquinolones and trimethoprim, as well as cefotaxime, has been demonstrated clearly [62].”
• Aminoglycoside Modifying Enzymes (2010, background): “, 2001); export outside the cell by active efflux pumps (Aires et al., 1999; Magnet et al., 2001; Rosenberg et al., 2000), one of which has recently been shown to be involved in adaptive resistance (Hocquet et al.”
• Clinically Relevant Chromosomally Encoded Multidrug Resistance Efflux Pumps in Bacteria (2006, methodology): “When adeB was deleted in a clinical isolate, BM4454, the organism became susceptible to gentamicin, ofloxacin, cefotaxime, and tetracycline (112), with MICs below the recommended breakpoint concentration (Table 5).”
• Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options (2017, background): “AdeABC in the resistance-nodulation-division superfamily is associated with aminoglycoside resistance (Magnet et al., 2001) and with decreasing susceptibility to tigecycline (Ruzin et al., 2007) and non-fluoroquinolone antibiotics (Higgins et al., 2004).”